Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma.
Novi
Marialuisa
M
Lauritano
Ernesto C
EC
Piscaglia
Anna C
AC
Barbaro
Brunella
B
Zocco
Maria A
MA
Pompili
Maurizio
M
Gasbarrini
Antonio
A
D000792:Angiography; D001557:Benzenesulfonates / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009360:Neoplastic Cells, Circulating / Q000187:drug effects / Q000473:pathology*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011169:Portal Vein / Q000473:pathology*; D011725:Pyridines / Q000008:administration & dosage*; D018570:Risk Assessment; D000077157:Sorafenib; D016896:Treatment Outcome
D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib